Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443407 | 1.00 | FKBP1A (0.33) | FKBP1ATOP2APPM1DDUT | |
| SCHEMBL22443492 | 1.00 | FKBP1A (0.33) | FKBP1ATOP2APPM1DDUT | |
| SCHEMBL22443764 | 0.92 | FKBP1A (0.32) | FKBP1ADUT | |
| SCHEMBL22443761 | 0.92 | FKBP1A (0.32) | FKBP1ADUT | |
| SCHEMBL24433847 | 0.86 | ALDH1A1 (0.33) | FKBP1ATOP2A | |
| SCHEMBL28662232 | 0.86 | ALDH1A1 (0.33) | FKBP1ATOP2A | |
| SCHEMBL22452856 | 0.86 | ALDH1A1 (0.33) | FKBP1ATOP2A | |
| SCHEMBL22453299 | 0.79 | — | — | |
| SCHEMBL24433887 | 0.78 | SPHK1 (0.33) | FKBP1ATOP2ADUT | |
| SCHEMBL28658942 | 0.78 | SPHK1 (0.33) | FKBP1ATOP2ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941468-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | FKBP1A 2968/4885TOP2A 3184/4885PPM1D 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.